Vir Biotechnology 2026: Revenue ($188K), Net income ($96.25M), EPS ($0.57) — 10-Q Summary

What happened

Vir Biotechnology reported 2026 revenue of $188K, down from $240K in the prior-year period. Its net loss narrowed to $96.25 million from $163.14 million, while diluted loss per share improved to $0.57 from $1.17. The company also reported progress across several drug-development programs.

Confirmed

Global impact / market context

The narrower loss and improved loss per share indicate lower reported losses than a year earlier, but revenue fell to $188K. For investors, progress in clinical trials and partnered programs could matter because future results, approvals, or partner funding may affect revenue and cash needs.

Analyst inference

The supplied figures show a company with very limited reported revenue alongside substantial net losses, so progress remains tied to drug development rather than current sales. Trial timelines and Gilead’s exclusive rights for three candidates shape potential future development and commercialization pathways.

Analyst inference

What to watch

1. Watch for ECLIPSE 1 topline results expected in Q4 2026; these trial results could clarify whether the CHD program is progressing toward regulatory review. Confirmed
2. Track whether VIR-5500 pivotal trials begin in 2027 as expected; pivotal trials are large studies intended to support a request for drug approval. Confirmed
3. Future updates on the Gilead agreement could clarify development responsibilities and economics, which may influence Vir’s spending needs and any potential revenue from the three candidates. Analyst inference

Evidence

• Original source link unavailable